

## **EXTENSION OF RIGHTS ISSUE CLOSING DATE**

*Not for release to US wire services or distribution in the United States except to eligible shareholders*

**May 26th, 2020. Melbourne, Australia.**

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, advises that the closing date for the fully underwritten renounceable rights issue (**Rights Issue**) has been extended to 5.00pm (AEST) on Tuesday, 9 June 2020.

The Company has extended the closing date of the Rights Issue to give those eligible shareholders who have experienced delays receiving physical mail as a result of COVID-19 restrictions further time to take up their entitlements. An updated timetable for the Rights Issue is provided below.

Application monies must be received prior to 5.00pm (AEST) on Tuesday, 9 June 2020, in accordance with the Prospectus and the personalised entitlement and acceptance form, which were despatched on 19 May 2020. The Company advises that eligible shareholders can download their personalised entitlement form and a copy of the Prospectus by registering for access at <https://investor.automic.com.au/#/home> or by contacting Automic on +61 2 9698 5414.

Shareholders with questions in relation to the Rights Issue may contact the Company on +61 3 8416 0900 at any time from 8.30am to 5.00pm (AEST) Monday to Friday (excluding public holidays) during the Rights Issue offer period.

# RHINOMED

MAKE EVERY BREATH COUNT

## Indicative timetable

Event	Date
Rights trading ends at the close of trading	Monday, 1 June 2020
Shares quoted on a deferred settlement basis from market open	Tuesday, 2 June 2020
Closing Date (5pm AEST)*	Tuesday, 9 June 2020
Announcement of results	Friday, 12 June 2020
Last date for issue of New Shares	Tuesday, 16 June 2020
Anticipated date for commencement of New Shares trading on a normal settlement basis	Wednesday, 17 June 2020

\* The above timetable is indicative only and subject to change. All references to time are to Australian Eastern Standard Time (AEST). The Company reserves the right, subject to the *Corporations Act 2001* (Cth), the ASX Listing Rules and other applicable laws, to extend the closing date or vary any other date of the rights issue without prior notice. Any extension of the closing date will have a consequential effect on the date of issue of New Shares.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

This announcement has been authorised for release to the market by the Board.

### Media Enquiries

Michael Johnson, CEO & Managing Director  
+61 (03) 8416 0900  
[mjohnson@rhinomed.global](mailto:mjohnson@rhinomed.global)

# RHINOMED

MAKE EVERY BREATH COUNT

Follow us on **Twitter** @rhinomedceo and @theturbinecom

## **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne based ASX listed airway technology company that has developed a simple and innovative nasal stent to improve oxygen flow to the lungs and deliver therapeutic agents.

With its initial product Turbine, Rhinomed has established a leading position in sports performance enhancement, as testified by athletes including two-time Tour de France winner Chris Froome. With its variant called Mute, the company has also entered the sleep sector to tackle the global snoring market while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is also developing applications for the delivery of medical cannabis products for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in nearly 15,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe and Australia.

[www.rhinomed.global](http://www.rhinomed.global)